Pembrolizumab in First-line Gastric Cancer: Win, Lose, or Draw?

JAMA Oncol. 2020 Oct 1;6(10):1539-1541. doi: 10.1001/jamaoncol.2020.2436.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Adenocarcinoma*
  • Antibodies, Monoclonal, Humanized
  • Humans
  • Stomach Neoplasms* / drug therapy

Substances

  • Antibodies, Monoclonal, Humanized
  • pembrolizumab